company background image
2269

WuXi Biologics (Cayman) SHSC:2269 Stock Report

Last Price

HK$72.65

Market Cap

HK$306.5b

7D

3.9%

1Y

-48.9%

Updated

30 Jun, 2022

Data

Company Financials +
2269 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

2269 Stock Overview

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People’s Republic of China, North America, Europe, and internationally.

WuXi Biologics (Cayman) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for WuXi Biologics (Cayman)
Historical stock prices
Current Share PriceHK$72.65
52 Week HighHK$148.00
52 Week LowHK$40.30
Beta1.14
1 Month Change25.26%
3 Month Change10.33%
1 Year Change-48.95%
3 Year Changen/a
5 Year Changen/a
Change since IPO-5.53%

Recent News & Updates

Shareholder Returns

2269HK Life SciencesHK Market
7D3.9%-6.0%1.1%
1Y-48.9%-46.7%-20.9%

Return vs Industry: 2269 underperformed the Hong Kong Life Sciences industry which returned -47% over the past year.

Return vs Market: 2269 underperformed the Hong Kong Market which returned -21.2% over the past year.

Price Volatility

Is 2269's price volatile compared to industry and market?
2269 volatility
2269 Average Weekly Movement9.9%
Life Sciences Industry Average Movement8.7%
Market Average Movement6.9%
10% most volatile stocks in HK Market13.7%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 2269 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 2269's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20149,864Chris Chenhttps://www.wuxibiologics.com

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People’s Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.

WuXi Biologics (Cayman) Fundamentals Summary

How do WuXi Biologics (Cayman)'s earnings and revenue compare to its market cap?
2269 fundamental statistics
Market CapCN¥261.77b
Earnings (TTM)CN¥3.39b
Revenue (TTM)CN¥10.29b

77.3x

P/E Ratio

25.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2269 income statement (TTM)
RevenueCN¥10.29b
Cost of RevenueCN¥5.49b
Gross ProfitCN¥4.80b
Other ExpensesCN¥1.42b
EarningsCN¥3.39b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.80
Gross Margin46.69%
Net Profit Margin32.93%
Debt/Equity Ratio8.4%

How did 2269 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 2269 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2269?

Other financial metrics that can be useful for relative valuation.

2269 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue24.8x
Enterprise Value/EBITDA70.4x
PEG Ratio3.3x

Price to Earnings Ratio vs Peers

How does 2269's PE Ratio compare to its peers?

2269 PE Ratio vs Peers
The above table shows the PE ratio for 2269 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average45.4x
1521 Frontage Holdings
44.7x28.0%HK$6.5b
1873 Viva Biotech Holdings
15.4x36.0%HK$5.2b
6118 Austar Lifesciences
4xn/aHK$1.3b
A207940 Samsung BiologicsLtd
117.2x12.7%₩56.2t
2269 WuXi Biologics (Cayman)
77.3x23.4%HK$306.5b

Price-To-Earnings vs Peers: 2269 is expensive based on its Price-To-Earnings Ratio (77.3x) compared to the peer average (45.4x).


Price to Earnings Ratio vs Industry

How does 2269's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

Price-To-Earnings vs Industry: 2269 is expensive based on its Price-To-Earnings Ratio (77.3x) compared to the Hong Kong Life Sciences industry average (15.6x)


Price to Earnings Ratio vs Fair Ratio

What is 2269's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2269 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio77.3x
Fair PE Ratio25.4x

Price-To-Earnings vs Fair Ratio: 2269 is expensive based on its Price-To-Earnings Ratio (77.3x) compared to the estimated Fair Price-To-Earnings Ratio (25.4x).


Share Price vs Fair Value

What is the Fair Price of 2269 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2269 (HK$72.65) is trading below our estimate of fair value (HK$86.49)

Significantly Below Fair Value: 2269 is trading below fair value, but not by a significant amount.


Price to Earnings Growth Ratio

PEG Ratio: 2269 is poor value based on its PEG Ratio (3.3x)


Discover undervalued companies

Future Growth

How is WuXi Biologics (Cayman) forecast to perform in the next 1 to 3 years based on estimates from 27 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


23.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2269's forecast earnings growth (23.4% per year) is above the savings rate (1.6%).

Earnings vs Market: 2269's earnings (23.4% per year) are forecast to grow faster than the Hong Kong market (17.1% per year).

High Growth Earnings: 2269's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 2269's revenue (23.8% per year) is forecast to grow faster than the Hong Kong market (10.2% per year).

High Growth Revenue: 2269's revenue (23.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2269's Return on Equity is forecast to be low in 3 years time (17.3%).


Discover growth companies

Past Performance

How has WuXi Biologics (Cayman) performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


53.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 2269 has a high level of non-cash earnings.

Growing Profit Margin: 2269's current net profit margins (32.9%) are higher than last year (30.1%).


Past Earnings Growth Analysis

Earnings Trend: 2269's earnings have grown significantly by 53.8% per year over the past 5 years.

Accelerating Growth: 2269's earnings growth over the past year (100.6%) exceeds its 5-year average (53.8% per year).

Earnings vs Industry: 2269 earnings growth over the past year (100.6%) exceeded the Life Sciences industry 45.8%.


Return on Equity

High ROE: 2269's Return on Equity (10.7%) is considered low.


Discover strong past performing companies

Financial Health

How is WuXi Biologics (Cayman)'s financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 2269's short term assets (CN¥19.5B) exceed its short term liabilities (CN¥8.3B).

Long Term Liabilities: 2269's short term assets (CN¥19.5B) exceed its long term liabilities (CN¥3.1B).


Debt to Equity History and Analysis

Debt Level: 2269 has more cash than its total debt.

Reducing Debt: 2269's debt to equity ratio has reduced from 351.5% to 8.4% over the past 5 years.

Debt Coverage: 2269's debt is well covered by operating cash flow (124.2%).

Interest Coverage: 2269 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is WuXi Biologics (Cayman) current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.07%

Forecast Dividend Yield

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2269's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2269's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2269's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2269's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 2269 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Chris Chen (48 yo)

6.42yrs

Tenure

CN¥50,794,000

Compensation

Dr. Zhisheng Chen, also known as Chris, has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr. Chen i...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD7.58M) is above average for companies of similar size in the Hong Kong market ($USD1.03M).

Compensation vs Earnings: Chris's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: 2269's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: 2269's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 2269 insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

WuXi Biologics (Cayman) Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: WuXi Biologics (Cayman) Inc.
  • Ticker: 2269
  • Exchange: SHSC
  • Founded: 2014
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$306.533b
  • Shares outstanding: 4.22b
  • Website: https://www.wuxibiologics.com

Number of Employees


Location

  • WuXi Biologics (Cayman) Inc.
  • No. 108, Meiliang Road
  • Mashan
  • Wuxi
  • Jiangsu Province
  • 214092
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/30 00:00
End of Day Share Price2022/06/29 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.